These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 4614897)

  • 1. Combination chemotherapy of bronchogenic carcinoma with cyclophosphamide (NSC-26271) and BCNU (NSC-409962).
    Curtis JE
    Cancer Chemother Rep; 1974; 58(6):883-8. PubMed ID: 4614897
    [No Abstract]   [Full Text] [Related]  

  • 2. Combination chemotherapy for bronchogenic carcinoma with doxorubicin, BCNU, and cyclophosphamide (ABC): a pilot study of the Southeastern Cancer Study Group.
    Denes AE; Presant CA; Bartolucci A
    Cancer Treat Rep; 1982 Jan; 66(1):199-200. PubMed ID: 7053258
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of cyclophosphamide (NSC-26271) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the treatment of patients with inoperable or disseminated lung cancer.
    Ahmann DL; Carr DT; Coles DT; Hahn RG
    Cancer Chemother Rep; 1972 Jun; 56(3):401-3. PubMed ID: 19051501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of long-term adjuvant chemotherapy with cyclophosphamide (NSC-26271) for radically resected bronchogenic carcinoma.
    Brunner KW; Marthaler T; Müller W
    Cancer Chemother Rep 3; 1973 Mar; 4(2):125-32. PubMed ID: 4199643
    [No Abstract]   [Full Text] [Related]  

  • 5. 5-Fluorouracil (NSC-19893) compared to cyclophosphamide (NSC-26271) in bronchogenic carcinoma: results of a clinical study.
    Brugarolas A; Rivas A; Lacave AJ; Gonzalez-Palacois F; Froufe A
    Cancer Chemother Rep; 1975; 59(5):1025-6. PubMed ID: 1106844
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase II study of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC No. 409962) with amphotericin B in bronchogenic carcinoma.
    Presant CA; Hillinger S; Klahr C
    Cancer; 1980 Jan; 45(1):6-10. PubMed ID: 6243243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with methyl-CCNU (NSC-95441), cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and bleomycin (NSC-125066) in advanced bronchogenic carcinoma.
    McMahon LJ; Jones SE; Durie BG; Salmon SE
    Cancer Lett; 1975 Nov; 1(2):97-102. PubMed ID: 65213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [VP 16-213 in combination with endoxan, methotrexate and oncovin as polychemotherapy for bronchogenic carcinoma].
    Ryssel HJ; Hasler E; Sonntag RW; Cavalli F; Martin J; Tschopp L; Brunner KW
    Schweiz Med Wochenschr; 1977 Jul; 107(26):912-5. PubMed ID: 877537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of combination chemotherapy with procarbazine (NSC-77213) and 5-fluorouracil (NSC-19893) in advanced carcinoma of the lung.
    Gottlieb JA; Serpick AA
    Cancer Chemother Rep; 1970 Oct; 54(5):369-71. PubMed ID: 5514626
    [No Abstract]   [Full Text] [Related]  

  • 10. Adriamycin (NSC-123127) in combination with cyclophosphamide (NSC-26271): a phase I and II evaluation.
    Muggia FM; Perloff M; Chia GA; Reed LJ; Escher GC
    Cancer Chemother Rep; 1974; 58(6):919-26. PubMed ID: 4614899
    [No Abstract]   [Full Text] [Related]  

  • 11. Cyclophosphamide (NSC-26271) as adjuvant to radiotherapy in the treatment of unresectable bronchogenic carcinoma.
    Host H
    Cancer Chemother Rep 3; 1973 Mar; 4(2):161-4. PubMed ID: 4729319
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cytostatic therapy of tumors of the lung].
    De Marco F; Saviano G; Tenore G
    Arch Monaldi; 1974; 29(3-4):326-35. PubMed ID: 4463917
    [No Abstract]   [Full Text] [Related]  

  • 13. [Trials of synchronized attack drug therapy in bronchogenic carcinoma].
    Seccia A; Scafuri L; Scognamillo A; Cocco G
    G Ital Chemioter; 1975; 22(1-2):63-6. PubMed ID: 1235355
    [No Abstract]   [Full Text] [Related]  

  • 14. Nitrosourea combinations in lung cancer.
    Livingston RB
    Cancer Treat Rep; 1976 Jun; 60(6):757-760. PubMed ID: 182365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remission maintenance of acute nonlymphoblastic leukemia with BCNU (NSC-409962) and cyclophosphamide (NSC-26271).
    Manaster J; Cowan DH; Curtis JE; Hasselback R; Bergsagel DE
    Cancer Chemother Rep; 1975; 59(3):537-45. PubMed ID: 1060509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BCNU (NSC-409962) in the treatment of bronchogenic carcinoma.
    Whittington RM; Fairly JL; Majima H; Patno ME; Prentice R
    Cancer Chemother Rep; 1972 Dec; 56(6):739-43. PubMed ID: 4574055
    [No Abstract]   [Full Text] [Related]  

  • 17. Bleomycin (NSC-125066) followed by cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and 5-fllorouracil (NSC-19893) for non-oat cell bronchogenic carcinoma.
    Lanzotti VJ; Thomas DR; Holoye PY; Boyle LE; Smith TL; Samuels ML
    Cancer Treat Rep; 1976 Jan; 60(1):61-8. PubMed ID: 63331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma.
    Evans WK; Feld R; DeBoer G; Osoba D; Curtis JE; Baker MA; Myers RE; Quirt IC; Pritchard KI; Brown TC; Kutas GJ; Blackstein ME; Ottema B; Millband L
    Cancer Treat Rep; 1981; 65(11-12):947-54. PubMed ID: 7028256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)--effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma.
    Bitran JD; Desser RK; DeMeester TR; Colman M; Evans R; Billings A; Griem M; Rubenstein L; Shapiro C; Golomb HM
    Cancer Treat Rep; 1976 Sep; 60(9):1225-30. PubMed ID: 189920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognostic factors in the chemotherapy of bronchial cancers].
    Alberto P
    Schweiz Med Wochenschr; 1974 Feb; 104(8):268-71. PubMed ID: 4360755
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.